Partnerships Partnering News

05.22.2017

Pharma Completes Patient Recruitment Of Recombinant Human Alkaline Phosphatase (Recap) Phase II Trial In Acute Kidney Injury

05.16.2017

Sangamo Receives Fast Track Designation From The Fda For Sb-525 Investigational Hemophilia A Gene Therapy

05.16.2017

Sangamo Receives Fast Track Designation From The Fda For Sb-525 Investigational Hemophilia A Gene Therapy

05.12.2017

TNO Starts Research Initiative With Industrial Partners To Combat Obesity-Associated Liver Disease

04.27.2017

Insphero Announces Agreement With Pfizer To Develop Novel Assays For Predicting Drug-Induced Liver Injury

04.25.2017

Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease

04.25.2017

Circle Pharma Announces Expansion Of Series A Financing And Appointment Of James C. Lu To Its Board

04.25.2017

Domain Therapeutics And Pfizer Inc. Enter Into Collaboration Agreement On Biosensall™

03.21.2017

NephCure Kidney International® Launches the NephCure Accelerating Cures Institute® Aims to accelerate treatments and a cure for glomerular kidney diseases

03.21.2017

New drug strategy: target the ribosome to halt protein production

03.17.2017

DILIsym Services, Inc. Evaluates Prospective NAFLD Treatment, Utilizing Its Flagship Technology in Collaboration with Pfizer, Inc.

03.01.2017

Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency